All In Biotech

Drug Trial Radar · NCT01064518

Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Last checked: Nov 19, 2026Latest source record: Aug 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Jan 2010

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Lead sponsor
Revance Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if an investigational drug, called RT001 Botulinum Toxin Type A Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called crow's feet, also known as lateral canthal lines.

Conditions

  • Lateral Canthal Lines
  • Crow's Feet
  • Facial Wrinkles

Interventions

  • Botulinum Toxin Type ADrug

    RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines

  • Placebo (Dose B)Drug

    Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects who show improvement based on the investigator global and patient assessments.Time frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Research Institute, LLC

    Coral Gables, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.